EQUITY ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Involving Possible Securities Fraud Violations by Certain Officers and Directors of Legend Biotech CorporationNewsfile Corp • 10/22/20
Legend Bio Investor Alert: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In Legend Biotech Corporation To Contact The FirmNewsfile Corp • 10/09/20
INVESTOR ALERT: Law Offices of Howard G. Smith Continues Investigation of Legend Biotech Corporation (LEGN) on Behalf of InvestorsBusiness Wire • 10/07/20
ROSEN, GLOBAL INVESTOR COUNSEL, Announces Investigation of Securities Claims Against Legend Biotech Corporation - LEGNNewsfile Corp • 09/26/20
ONGOING INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Legend Biotech Corporation and Encourages Investors with Losses of $100,000 to Contact the FirmNewsfile Corp • 09/25/20
ROSEN LAW FIRM, GLOBAL INVESTOR COUNSEL, Announces Investigation of Securities Claims Against Legend Biotech Corporation – LEGNBusiness Wire • 09/25/20
Glancy Prongay & Murray LLP Continues Investigation on Behalf of Legend Biotech Corporation Investors (LEGN)Business Wire • 09/23/20
The Law Offices of Frank R. Cruz Announces Investigation of Legend Biotech Corporation (LEGN) on Behalf of InvestorsBusiness Wire • 09/22/20
INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Legend Biotech Corporation and Encourages Investors with Losses of $100,000 to Contact the FirmBusiness Wire • 09/22/20
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Legend Biotech Corporation (LEGN) on Behalf of InvestorsBusiness Wire • 09/22/20
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Legend Biotech Corporation (LEGN) on Behalf of InvestorsBusiness Wire • 09/22/20
SHAREHOLDER ALERT: Investigation of Legend Biotech Announced by Holzer & Holzer, LLCBusiness Wire • 09/21/20
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Legend Biotech Corporation and Encourages Investors with Losses of $100,000 to Contact the FirmBusiness Wire • 09/21/20
Legend Biotech Names Current Chief Financial Officer, Ying Huang, as Interim CEOBusiness Wire • 09/21/20
Legend Biotech to Participate in the 18th Annual Morgan Stanley Virtual Global Healthcare ConferenceBusiness Wire • 09/01/20
The China Center for Drug Evaluation, National Medical Products Administration Has Recommended Breakthrough Therapy Designation for ciltacabtagene autoleucel (cilta-cel, LCAR-B38M CAR-T Cells), an Investigational BCMA CAR-T Cell TherapyBusiness Wire • 08/05/20